http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-600539-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_755b91092aa6defa5c927ce3295a378c
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-34
filingDate 2010-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a6dabf6aee4cb87fdb0529bc94d5190
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9e45c53d7484ba045bd4915ded1883b
publicationDate 2014-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-600539-A
titleOfInvention Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome
abstract A parenteral pharmaceutical formulation in suspension, for sustained release, containing suspended estradiol and progesterone particles for hormonal replacement in female mammals in low and ultra-low dose, in the form of an injectable suspension comprising estradiol particles, progesterone particles, a surfactant agent, an isosmotic agent, a viscous increasing agent and one or more preservatives, wherein: the low-dose formulation comprises between 0.5mg to 1.0mg of estradiol and between 20mg to 75mg of progesterone, and the ultra-low does formulation comprises 0.25 to 0.50mg of estradiol and 15.0mg of progesterone. The estradiol may be in particles having a size between 1 and 100 microns and the progesterone is in particles having a size between 1 and 100 microns and it may be for application thereof in parenteral, intramuscular, subcutaneous or intradermal pharmaceutical form.
priorityDate 2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554556
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134688829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323226
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5757
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5994

Total number of triples: 35.